PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis

This report provides an overrview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines
 
 
Spread the Word
Listed Under

Tags:
PharmaPoint
Epilepsy
Global Drug

Industry:
Health

Location:
London City - London, Greater - England

Feb. 12, 2013 - PRLog -- President Obama’s Affordable Care Act (ACA) will be an important factor in driving up the value of the US epilepsy pharmaceuticals market, predicts a new report from research and consulting firm GlobalData.

The company’s latest publication* forecasts the US epilepsy market to climb from a value of US$2 billion in 2012 to US$2.8 billion by the end of 2022 at a Compound Annual Growth Rate (CAGR) of 3.4%. The increase will see the US claim more than half of the global market during this period, increasing its share from 49% to 52%.

Under the current US healthcare coverage scenario, there is a treatment gap of 10% which accounts for almost 200,000 epilepsy patients at any given time. The individual mandate of the ACA, to be implemented in 2014, is predicted to increase health insurance coverage and improve access to doctors, resulting in greater treatment and prescription rates.

For Sample Pages, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceutical...

GlobalData also believes the entrance of new Anti-Epilepsy Drugs (AED) with distinctly different Mechanisms of Action (MOA) will prove the key driver for epilepsy pharmaceutical sales in the near future. Medications such as Potiga and Fycompa, both of which have recently received FDA approval, are generating interest among patients and physicians alike, thanks to first-in-class novel MOAs.

Both drugs are expected to be priced at a premium when compared to other AEDs on the market, and their adoption and continued use over the next decade will be a major industry revenue generator.

According to the new report, the global epilepsy market is expected to grow from  value of US$4.2 billion in 2012 to US$5.5 billion 10 years later, demonstrating a CAGR of 2.8%

This report provides an overrview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceutical...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com



North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782
End
Source:
Email:***@globaldata.com Email Verified
Phone:+914066166782
Zip:EC4Y 0AN
Tags:PharmaPoint, Epilepsy, Global Drug
Industry:Health
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GlobalData PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share